GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Cyclically Adjusted PS Ratio

Repligen (Repligen) Cyclically Adjusted PS Ratio : 22.90 (As of Apr. 29, 2024)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Repligen's current share price is $166.95. Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $7.29. Repligen's Cyclically Adjusted PS Ratio for today is 22.90.

The historical rank and industry rank for Repligen's Cyclically Adjusted PS Ratio or its related term are showing as below:

RGEN' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 9.06   Med: 24.59   Max: 79.23
Current: 22.86

During the past years, Repligen's highest Cyclically Adjusted PS Ratio was 79.23. The lowest was 9.06. And the median was 24.59.

RGEN's Cyclically Adjusted PS Ratio is ranked worse than
96.13% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.12 vs RGEN: 22.86

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Repligen's adjusted revenue per share data for the three months ended in Dec. 2023 was $2.790. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $7.29 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Repligen Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Repligen's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Cyclically Adjusted PS Ratio Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.76 55.67 55.59 27.21 24.68

Repligen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.21 25.59 20.62 22.42 24.68

Competitive Comparison of Repligen's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted PS Ratio falls into.



Repligen Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Repligen's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=166.95/7.29
=22.90

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Repligen's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.79/129.4194*129.4194
=2.790

Current CPI (Dec. 2023) = 129.4194.

Repligen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.497 99.695 0.645
201406 0.470 100.560 0.605
201409 0.458 100.428 0.590
201412 0.486 99.070 0.635
201503 0.622 99.621 0.808
201506 0.637 100.684 0.819
201509 0.588 100.392 0.758
201512 0.641 99.792 0.831
201603 0.749 100.470 0.965
201606 0.854 101.688 1.087
201609 0.719 101.861 0.914
201612 0.745 101.863 0.947
201703 0.890 102.862 1.120
201706 0.925 103.349 1.158
201709 0.859 104.136 1.068
201712 0.936 104.011 1.165
201803 1.011 105.290 1.243
201806 1.060 106.317 1.290
201809 1.081 106.507 1.314
201812 1.117 105.998 1.364
201903 1.310 107.251 1.581
201906 1.441 108.070 1.726
201909 1.340 108.329 1.601
201912 1.310 108.420 1.564
202003 1.433 108.902 1.703
202006 1.641 108.767 1.953
202009 1.759 109.815 2.073
202012 1.952 109.897 2.299
202103 2.512 111.754 2.909
202106 2.870 114.631 3.240
202109 3.107 115.734 3.474
202112 3.225 117.630 3.548
202203 3.509 121.301 3.744
202206 3.661 125.017 3.790
202209 3.503 125.227 3.620
202212 3.275 125.222 3.385
202303 3.202 127.348 3.254
202306 2.799 128.729 2.814
202309 2.480 129.860 2.472
202312 2.790 129.419 2.790

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Repligen  (NAS:RGEN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Repligen Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Repligen's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines